Seegene

Seegene Net Debt per Share

The Net Debt per Share of Seegene (096530.KQ) as of Oct 31, 2026 is 5.03 KRW. In the previous year, Net Debt per Share was 16.54 KRW — a change of -69.61% (lower).

Net Debt per Share

5.03KRW

YoY

-69.61%

Last updated:

Net Debt per Share of Seegene is 2025 5.03 KRW. Net Debt per Share of Seegene was 2024 16.54 KRW. It decreases by -69.61% lower compared to the previous year.

The Seegene Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-734.62 KRW
Jan 1, 2019
-1,104.90 KRW
Jan 1, 2020
-4,727.88 KRW
Jan 1, 2021
-6,811.42 KRW
Jan 1, 2022
-9,632.37 KRW
Jan 1, 2023
30.84 KRW
Jan 1, 2024
16.54 KRW
Jan 1, 2025
5.03 KRW
The Seegene Net Debt per Share history
YEARNet Debt per ShareYoY
5.03KRW-69.61%
16.54KRW-46.36%
30.84KRW-100.32%
-9,632.37KRW+41.42%
-6,811.42KRW+44.07%
-4,727.88KRW+327.90%
-1,104.90KRW+50.40%
-734.62KRW+47.72%
-497.32KRW-32.35%
-735.10KRW+9.56%
-670.93KRW-200.88%
665.07KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Net Debt per Share of Seegene is 5.03 KRW in 2025.

Net Debt per Share of Seegene changed from 16.54 KRW to 5.03 KRW, representing a -69.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Seegene since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Seegene

All Key Metrics — Seegene